NCT04222725View on ClinicalTrials.gov

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

July 17, 2020

Study Completion Date

July 17, 2020

Conditions

Post Surgical Ocular Inflammation

Interventions

DRUG

TRS01 eye drops

Dosed 4 times a day (QID)

DRUG

TRS01 eye drops

Dosed QID

DRUG

TRS01 eye drops

Dosed QID

DRUG

Placebo eye drops

Dosed QID

Trial Locations (5)

10013

New York, New York

45242

Cincinnati, Cincinnati

63090

Washington, MO, Washington

90302

Inglewood, Inglewood

94954

Petaluma, Petaluma

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Tarsier Pharma

INDUSTRY